• FDA Formally Withdraws Approval for Second Generic Version of Popular Antidepressant

    This week the US Food and Drug Administration (FDA) formally-and quietly-withdrew a generic version of GlaxoSmithKline's Wellbutrin XL (bupropion) 300 mg following a determination that the drug was not bioequivalent to its originator. Background The withdrawal of the generic buproprion, an antidepressant marketed by Watson Pharmaceuticals, follows similar concerns raised about other generic versions of bupropion. In September 2012, FDA announced that it had asked Israe...